Positive vs Negative Symptoms of Schizophrenia Explained

Schizophrenia is one of the most misunderstood mental health conditions, partly because of confusing medical terminology. When doctors discuss positive vs negative symptoms of schizophrenia, they are not referring to “good” and “bad” symptoms. Instead, these terms describe whether the symptom represents something added to or taken away from normal functioning.

Understanding positive vs negative symptoms of schizophrenia is critical for patients, caregivers, and anyone seeking to understand this complex disorder. The distinction affects treatment approaches, prognosis, and daily management. According to the National Institute of Mental Health (NIMH), schizophrenia affects roughly a quarter to two-thirds of one percent of people in the United States (commonly cited estimates fall around 0.25 to 0.64 percent, with prevalence varying by how it is measured), and its symptoms typically emerge in late adolescence or early adulthood. It is also important to say plainly: schizophrenia is a medical condition, not a character flaw or a sign of a “split personality,” and most people living with it are far more likely to be victims of harm than to cause it. Accurate language helps reduce the stigma that keeps people from seeking care.

What Are Positive Symptoms of Schizophrenia?

Positive symptoms are experiences or behaviors that are “added” to a person’s normal functioning. They represent distortions or excesses of normal mental processes. These symptoms are called “positive” not because they are beneficial but because they represent the presence of something that should not be there.

The major positive symptoms include:

Hallucinations. These are sensory experiences that occur without an external stimulus. Auditory hallucinations, particularly hearing voices, are the most common type, affecting a majority of people with schizophrenia (research published in Schizophrenia Bulletin has reported figures in the range of roughly 60 to 80 percent). The voices may comment on the person’s behavior, give commands, or carry on conversations. Visual, tactile, olfactory, and gustatory hallucinations can also occur but are less common.

Delusions. These are firmly held false beliefs that persist despite contradictory evidence. The Cleveland Clinic categorizes common delusion types as persecutory (believing others are trying to harm you), grandiose (believing you have special powers or importance), referential (believing that random events are directed at you), and erotomanic (believing someone of higher status is in love with you). Delusions of control, where a person believes their thoughts or actions are being controlled by an outside force, are particularly characteristic of schizophrenia.

Disorganized thinking and speech. This manifests as difficulty organizing thoughts into logical sequences. Speech may become incoherent, jump between unrelated topics (derailment), or include invented words (neologisms). In severe cases, speech can become so fragmented that it is incomprehensible, a condition sometimes called “word salad.”

Disorganized or abnormal motor behavior. This can range from childlike silliness to unpredictable agitation. It may include catatonia, a state of apparent unresponsiveness to the environment that can involve rigid posture, lack of movement, or excessive purposeless movement.

What Are Negative Symptoms of Schizophrenia?

Negative symptoms represent a reduction or absence of normal functions and behaviors. They are called “negative” because they reflect something that has been taken away from the person’s baseline functioning. These symptoms are often more subtle than positive symptoms and can be easily mistaken for depression, laziness, or lack of motivation — a misreading that can be deeply unfair to the person experiencing them.

The five recognized negative symptoms, sometimes referred to as the “five As,” include:

Affective flattening (blunted affect). This involves a reduction in the range and intensity of emotional expression. The person’s face may appear immobile and unresponsive, with poor eye contact and reduced body language. Their voice may become monotone. It is important to note that blunted affect refers to the outward expression of emotions, not necessarily the internal experience. Some individuals with flat affect report still feeling emotions internally but being unable to express them.

Alogia (poverty of speech). This manifests as a decrease in speech output or content. The person may give brief, empty replies to questions or may stop speaking entirely in some cases. When they do speak, their responses may lack detail or spontaneity.

Anhedonia. This is the reduced ability to experience pleasure from activities that were previously enjoyable. A person who once loved music, cooking, or socializing may show little interest in these activities. Research suggests that anhedonia in schizophrenia may involve deficits in anticipatory pleasure, the ability to look forward to future pleasurable experiences, more than consummatory pleasure, the ability to enjoy something in the moment.

Avolition. This refers to a decrease in motivation to initiate and sustain purposeful activities. A person with avolition may sit for hours without engaging in any activity, neglect personal hygiene, or be unable to follow through on plans or goals. This is not laziness but a genuine deficit in the brain’s motivation circuitry, and treating it as a moral failing tends to make things worse.

Asociality. This involves reduced social interaction and interest in forming relationships. The person may withdraw from friends and family, prefer solitude, and show little interest in social activities. This differs from social anxiety in that the person is typically not fearful of social situations but rather indifferent to them.

Why the Distinction Matters for Treatment

The differentiation between positive vs negative symptoms of schizophrenia has significant implications for treatment. Antipsychotic medications, the primary pharmacological treatment for schizophrenia, are generally more effective at treating positive symptoms than negative symptoms. All of the medications discussed below are prescription treatments that must be selected, dosed, and monitored by a qualified clinician; this article describes categories of treatment for educational purposes and does not recommend any specific drug or dose.

First-generation (typical) antipsychotics such as haloperidol and chlorpromazine primarily target dopamine receptors and can be very effective at reducing hallucinations, delusions, and disorganized thinking. However, they have limited impact on negative symptoms and can sometimes appear to worsen them through side effects such as emotional blunting and sedation.

Second-generation (atypical) antipsychotics such as clozapine, risperidone, and olanzapine affect both dopamine and serotonin receptors and are generally considered somewhat more helpful for negative symptoms, though the improvement is often modest. Clozapine, in particular, has the strongest evidence for treatment-resistant cases, according to the Mayo Clinic, but it requires regular blood monitoring and is used under close clinical supervision.

A newer approach: muscarinic-targeting medication. In September 2024, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. What makes it notable is its mechanism: rather than directly blocking dopamine D2 receptors the way older antipsychotics do, it acts on the brain’s muscarinic cholinergic system (xanomeline is a muscarinic agonist, paired with trospium to limit side effects outside the brain). This gives it a different side-effect profile than traditional antipsychotics and represents the first genuinely new pharmacological approach to schizophrenia in decades. As with any newer medication, its long-term role, cost, and comparative benefit for negative and cognitive symptoms are still being studied, and whether it is appropriate for a given person is a decision for the treating psychiatrist.

The persistent challenge of treating negative symptoms continues to drive research. Clinical trials are exploring additional approaches including glutamate modulators, anti-inflammatory agents, and targeted cognitive interventions. Psychosocial treatments such as cognitive behavioral therapy for psychosis, social skills training, and supported employment programs can also help address the functional impairments associated with negative symptoms, and they work best alongside — not instead of — medical treatment.

How Positive and Negative Symptoms Affect Daily Life

Positive symptoms tend to be more dramatic and are usually what prompts initial psychiatric evaluation. Hearing voices or expressing delusional beliefs is noticeable to others and often leads to emergency room visits. These symptoms can be frightening for both the individual and those around them, and they often represent the public’s stereotypical image of schizophrenia — even though they are only one part of the condition.

Negative symptoms, while less dramatic, often have a greater impact on long-term functioning and quality of life. Research published in the American Journal of Psychiatry and elsewhere has consistently found that negative symptoms are stronger predictors of functional outcomes — including the ability to work, maintain relationships, and live independently — than positive symptoms.

A person whose positive symptoms are well-controlled by medication may still struggle significantly if their negative symptoms persist. They may have difficulty maintaining employment because of avolition, struggle to maintain relationships because of asociality and flat affect, and find little enjoyment in daily activities because of anhedonia. These challenges often go unrecognized because the person appears “stable” once their hallucinations and delusions are managed.

Caregivers frequently report that negative symptoms are more burdensome than positive symptoms in the long term. While positive symptoms can be alarming, they are often episodic and respond to medication adjustments. Negative symptoms tend to be chronic, persistent, and resistant to current treatments, creating ongoing challenges for patients and families alike.

Cognitive Symptoms: The Third Category

In addition to positive and negative symptoms, schizophrenia also involves cognitive symptoms that affect thinking processes. While not formally classified in the positive vs negative framework, cognitive symptoms are increasingly recognized as a core feature of the disorder. These include:

• Difficulty with attention and concentration
• Impaired working memory, making it hard to use information immediately after learning it
• Reduced processing speed
• Problems with executive function, including planning, organizing, and decision-making
• Difficulty understanding and using social cues

The NIMH notes that cognitive deficits are present in the majority of people with schizophrenia and, like negative symptoms, are strong predictors of functional outcomes. Cognitive remediation therapy, a structured program designed to improve specific thinking skills, has shown modest benefits in clinical trials and is increasingly available as part of comprehensive treatment programs. Interest in whether newer medications can meaningfully improve cognition is one reason drugs with novel mechanisms are being watched closely.

Diagnosis and Assessment

Diagnosing schizophrenia and assessing the balance of positive and negative symptoms requires a thorough psychiatric evaluation. According to the DSM-5-TR, a diagnosis of schizophrenia requires the presence of at least two of the following for a significant portion of a one-month period: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. At least one of these must be delusions, hallucinations, or disorganized speech, and signs of disturbance must persist for at least six months.

Standardized rating scales are used to assess symptom severity. The Positive and Negative Syndrome Scale (PANSS) is the most widely used clinical tool, measuring 30 items across positive symptoms, negative symptoms, and general psychopathology. The Scale for the Assessment of Negative Symptoms (SANS) provides a more detailed evaluation of specific negative symptom domains.

Importantly, other conditions must be ruled out before a schizophrenia diagnosis is made. Substance use, medical conditions such as brain tumors or autoimmune encephalitis, mood disorders with psychotic features, and other psychotic disorders can all produce symptoms that overlap with schizophrenia. Brain imaging and laboratory tests may be used to exclude these alternative diagnoses. Because the diagnosis carries lifelong implications, it should be made by a qualified mental health professional, not self-diagnosed from a symptom list. For more information on medical assessments, visit our medical conditions guide.

Supporting Someone With Schizophrenia

If you are a caregiver or family member of someone with schizophrenia, understanding the positive vs negative symptoms distinction can help you provide more effective support. For positive symptoms, it is important to remain calm during psychotic episodes, avoid arguing about delusions or hallucinations, support medication adherence, and know when to seek emergency help.

For negative symptoms, strategies include setting small, achievable goals rather than expecting large behavioral changes, encouraging activity without being pushy, maintaining social connections even when the person seems uninterested, celebrating small accomplishments, and seeking out psychosocial rehabilitation programs that can provide structure and support.

The National Alliance on Mental Illness (NAMI) offers family education programs, support groups, and resources specifically for caregivers of people with schizophrenia (NAMI also operates a HelpLine for information and referrals). Research consistently shows that family involvement and support are associated with better treatment outcomes and reduced relapse rates. And because untreated psychosis and early illness carry a heightened suicide risk, families should know the warning signs and keep the 988 Suicide & Crisis Lifeline (call or text 988) and 911 readily available.

Frequently Asked Questions

Which type of symptom appears first in schizophrenia?

Research suggests that negative symptoms and subtle cognitive changes often appear before positive symptoms, sometimes by months or even years. This early phase is called the prodromal period. During this time, a person may gradually become more socially withdrawn, lose motivation, decline in academic or work performance, and develop unusual beliefs or perceptual experiences that fall short of full-blown delusions or hallucinations. Positive symptoms such as hallucinations and delusions typically emerge later and often mark the transition to the active phase of the illness. Early intervention during the prodromal period is an active area of research, as treatment at this stage may improve long-term outcomes — which is one reason getting evaluated early, rather than waiting, matters so much.

Can positive symptoms become negative symptoms over time?

Positive and negative symptoms do not directly convert into each other, but the symptom profile of schizophrenia can shift over time. In many cases, the acute positive symptoms that characterize early episodes become less prominent with age and treatment, while negative symptoms become more dominant. However, this trajectory is not universal, and individual experiences vary widely. Some people maintain prominent positive symptoms throughout their lives, while others achieve significant remission of both symptom types.

Are negative symptoms of schizophrenia the same as depression?

While there is significant overlap between negative symptoms and depression — particularly in areas such as reduced motivation, social withdrawal, and diminished interest in activities — they are distinct phenomena. Depression involves a pervasive low mood and often includes feelings of sadness, guilt, worthlessness, and suicidal ideation. Negative symptoms of schizophrenia involve a reduction in emotional expression and motivation but do not necessarily include the subjective experience of sadness. A person with prominent negative symptoms may appear emotionally flat but deny feeling sad when asked. Depression can also co-occur with schizophrenia, complicating the clinical picture, and because depression raises suicide risk, it should be evaluated and treated. Accurate differentiation is important because the treatment approaches differ.

What is the prognosis for people with predominantly negative symptoms?

People with predominantly negative symptoms generally face a more challenging prognosis in terms of functional outcomes. They are more likely to have difficulty with employment, independent living, and social relationships. However, this does not mean recovery is impossible. Comprehensive treatment that includes psychosocial interventions, vocational rehabilitation, and supported housing can significantly improve quality of life. Research is ongoing to develop more effective treatments specifically targeting negative symptoms, and newer pharmacological approaches offer cautious hope for this underserved group of patients.

Can schizophrenia be treated successfully?

Yes. Schizophrenia is a chronic condition, but it is treatable, and many people live meaningful, productive lives with appropriate care. The most consistent predictors of better outcomes are early treatment, staying connected to care, and continuing medication as prescribed rather than stopping when symptoms improve. Stopping antipsychotics abruptly is one of the most common causes of relapse, so any change should be made with a clinician. If symptoms worsen or a crisis develops, contact the treating provider, and in an emergency call or text 988 or call 911.

Understanding positive vs negative symptoms of schizophrenia provides a framework for comprehending this complex disorder. By recognizing the different symptom types, patients, caregivers, and healthcare providers can work together more effectively to develop treatment plans that address the full spectrum of challenges associated with schizophrenia. This article is educational and does not replace evaluation and treatment by a qualified mental health professional.

Sources

• National Institute of Mental Health (NIMH) — Schizophrenia (overview, prevalence, symptoms, and treatment)
• U.S. Food and Drug Administration — Approval of Cobenfy (xanomeline and trospium chloride), September 2024
• Cleveland Clinic — Schizophrenia and types of delusions
• Mayo Clinic — Schizophrenia diagnosis and treatment
• National Alliance on Mental Illness (NAMI) — caregiver resources and HelpLine
• 988 Suicide & Crisis Lifeline (call or text 988)